The AGILE clinical trial platform has been launched specifically to test new COVID-19 treatments, faster than ever before. It bridges the gap between non-human trials and large-scale testing, so potential new treatments can go through the important testing stages in a matter of months rather than years, while maintaining a high level of safety at all times.

AGILE is an adaptive randomized seamless Phase I/II trial platform that seeks to quickly establish a safe range of doses and investigates treatments for potential efficacy using a Bayesian sequential trial design. At present one candidate drug is being investigated in the UK while several others are expected to start recruiting in UK and international sites in the near future.

A bespoke design has been developed for the study by a team, including Programme Leader Thomas Jaki, that uses a randomized dose-finding approach together with a Bayesian sequential survival model.

Find out more: https://www.agiletrial.net/